Amylyx Pharmaceuticals chief legal officer sells $31,954 in stock

CAMBRIDGE, MA—Gina Mazzariello, the Chief Legal Officer of Amylyx Pharmaceuticals , Inc. (NASDAQ:AMLX), recently sold 9,192 shares of the company’s common stock. The transaction, which took place on March 31, 2025, was valued at approximately $31,954, with shares sold at a weighted average price of $3.4763. The stock, currently trading at $3.78, has shown resilience with a 27% gain over the past year despite broader market challenges. According to InvestingPro analysis, AMLX appears undervalued based on its Fair Value metrics.

The sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units, as noted in the filing. Following this transaction, Mazzariello holds 187,969 shares of Amylyx Pharmaceuticals. The shares were sold in multiple transactions with prices ranging from $3.44 to $3.58. With a market capitalization of $296 million and its next earnings report due on May 8, 2025, investors seeking deeper insights can access comprehensive analysis through InvestingPro’s detailed research reports, which cover over 1,400 US stocks.

In other recent news, Amylyx Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its Phase 1 trial for AMX0114, a potential treatment for amyotrophic lateral sclerosis (ALS). This decision allows the company to proceed with patient screening, enrollment, and dosing at trial sites across the United States. The clinical trial, named LUMINA, will also begin in Canada early this year and is designed as a multicenter, randomized, placebo-controlled study. Approximately 48 individuals with ALS will participate, with a 3:1 randomization to receive either the investigational drug or a placebo.

Amylyx plans to evaluate the safety and biological activity of AMX0114, which targets calpain-2, a protein associated with neurodegenerative processes. The trial will monitor changes in neurofilament light (NfL) levels, a biomarker for ALS. Preclinical models have shown that AMX0114, an antisense oligonucleotide (ASO), can reduce CAPN2 mRNA and calpain-2 protein levels, leading to improved neuronal survival. The company anticipates sharing early cohort data from the LUMINA trial within the year.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.